Adenovirus-specific Cytotoxic T-lymphocytes for Refractory Adenovirus Infection
Key facts
- Who runs it
- New York Medical College
- Where
- Aurora, Baltimore, Columbus, Indianapolis, Los Angeles, Milwaukee, Philadelphia, San Francisco, and St Louis, United StatesSee the 10 sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 20 people, planned
- Started
- 1 Nov 2018
- Expected to end
- 31 Dec 2027
- Type of study
- Interventional
- Treatments tested
- cytotoxic t-lymphocytes
- Record updated
- 23 October 2026
Who can take part
- Age
- 1 month to 79 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (3)Hide the full registry criteria
Other criteria
- Patients with Adenovirus infections post allogeneic HSCT, with primary immunodeficiencies or post solid organ transplant with:; Increasing or persistent quantitative ADV RT-PCR DNA copies despite two weeks of appropriate anti-viral therapy and/or; clinical symptoms attributed to adenovirus, including pneumonitis, hemorrhagic cystitis, colitis, hepatitis AND/OR; Medical intolerance to anti-viral therapies including:; grade 2 renal insufficiency secondary to cidofovir Consent: Written informed consent given (by patient or legal representative) prior to any study-related procedures; Performance Status > 30% (Lansky < 16 yrs and Karnofsky > 16 yrs) Age: 0.1 to 79 years; Females of childbearing potential with a negative urine pregnancy test
- Donor Eligibility Related donor available with a T-cell response to the viral MACS® GMP PepTivator antigen(s) of adenovirus; Third Party Related Allogeneic Donor: If original donor is not available or does not have a T-cell response: third party allogeneic donor (family donor > 1 HLA A, B, DR match to recipient) with a T-cell response at least to the viral MACS® GMP PepTivator antigen(s) of adenovirus; AND Allogeneic donor disease screening is complete similar to hematopoietic stem cell donors (Appendix 1); AND Obtained informed consents by donor or donor legally authorized representative prior to donor collection
- Patient exclusion criteria:; A patient meeting any of the following criteria is not eligible for the present study:; . Patient with acute GVHD > grade 2 or extensive chronic GVHD at the time of CTL infusion Patient receiving steroids (>0.5 mg/kg prednisone equivalent) at the time of CTL infusion Patient treated with donor lymphocyte infusion (DLI) within 4 weeks prior to CTL infusion Patient with poor performance status determined by Karnofsky (patients >16 years) or Lansky (patients ≤16 years) score ≤30% Concomitant enrollment in another experimental clinical trial investigating the treatment of refractory adenovirus infection(s) Any medical condition which could compromise participation in the study according to the investigator's assessment Known HIV infection Female patient of childbearing age who is pregnant or breast-feeding or not willing to use an effective method of birth control during study treatment; Known hypersensitivity to iron dextran Patients unwilling or unable to comply with the protocol or unable to give informed consent; Known human anti-mouse antibodies; -
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Adenovirus or primary immune deficiency disorder
This trial is currently available in United States.
- Children's Hospital of ColoradoAurora, United StatesContact: Michael Verneris, MDTaking people
- University of Colorado DenverAurora, United StatesContact: Michael Verneris, MDTaking people
- Johns HopkinsBaltimore, United StatesContact: Kenneth Cooke, MDNot yet recruiting
- Nationwide Children's HosptialColumbus, United StatesContact: Dean Lee, MD, PhDTaking people
- Indiana UniversityIndianapolis, United StatesContact: Emily Hopewell, MDTaking people
- Children's Hospital Los AngelesLos Angeles, United StatesContact: Neena Kapoor, MDTaking people
- Medical College of Wisconsin/Children's Hospital of WisconsinMilwaukee, United StatesContact: Julie A Talano, MDTaking people
- Children's Hospital of PennsylvaniaPhiladelphia, United StatesContact: Nancy Bunin, MDTaking people
- University of California San FranciscoSan Francisco, United StatesContact: Julia Chu, MDTaking people
- Washington UniversitySt Louis, United StatesContact: Shalini Shenoy, MDTaking people
About the trial
What the trial wants to find out
Related donor Adenovirus (ADV) specific cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System will be administered intravenously in in children, adolescents and young adults with refractory ADV infection post Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT), with primary immunodeficiencies (PID) or post solid organ transplant.
Read full original descriptionShow less
Funding Source: FDA OOPD
The group in the trial
- patients with adenoviral infectionTreatment being tested
patients will receive CTL dose x 1 with 2.5 × 10(4) CD3/kg for matched related donor and 0.5 × 104 CD3/kg for mis-matched related donor. Patients who don't respond to the first infusion may receive up to a total 5 CTL infusions.
Treatment: cytotoxic t-lymphocytes
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Pilot Study in the Treatment of Refractory Adenovirus (ADV) Infection With Related Donor ADV Cytotoxic T-Lymphocytes (ADV-CTLs)in Children, Adolescents and Young Adult Recipients
- Criteria questions
- Built from NCT03266627, who can take part
- Record updated
- 23 October 2026